Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
12/2005
12/01/2005US20050266519 Methods and compositions for modulating and detecting activin dimer and dimer formation
12/01/2005US20050266506 Method for diagnosing or monitoring carbohydrate metabolism disorders
12/01/2005US20050266504 Diagnosing nervous system disorders; obtain tissue sample, measure expression of semaphorin 3 and downstream effectors , amplified concentrations of semaphorins indicate nervous system disorders; drug screening
12/01/2005US20050266486 Methods for treating obesity by inhibiting expression of obese gene product receptor variant
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266484 gene therapy; a sequence which encodes the polypeptide podocin; proteinuria
12/01/2005US20050266479 Cloning, expression and characterization of the SPG4 gene responsible for the most common form of autosomal dominant spastic paraplegia
12/01/2005US20050266477 Reagents and methods useful for detecting diseases of the gastrointestinal tract
12/01/2005US20050266470 25501, a human transferase family member and uses therefor
12/01/2005US20050266461 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/01/2005US20050266451 Obtaining antibodies with desired characteristics by isolating complementary determining regions DNA sequences and incorporating them into scaffold; shuffling polynucleotide sequences
12/01/2005US20050266445 Purified mammalian CTLA-8 antigens and related reagents
12/01/2005US20050266435 VR1 receptors and uses thereof
12/01/2005US20050266430 A mutated G-CSF mRNA or cDNA fragment having a deletion of an exon 3 region for use; primer for use in amplification of a G-CSF gene
12/01/2005US20050266426 Confluence regulated adhesion molecules useful in modulating vascular permeability
12/01/2005US20050266425 Methods for producing and identifying multispecific antibodies
12/01/2005US20050266423 Novel nucleic acids and polypeptides
12/01/2005US20050266399 HCV regulated protein expression
12/01/2005US20050266022 Methods and compositions for use in the treatment of filovirus mediated disease conditions
12/01/2005US20050266016 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
12/01/2005US20050266013 Diagnosis of RH factor; using polypeptides to form antibodies; purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens for treating idiopathic thrombocytopenic purpura (ITP) or mistransfusion of Rhesus incompatible blood
12/01/2005US20050266010 Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
12/01/2005US20050266009 Antibodies and uses thereof
12/01/2005US20050266008 Human anti-IRTA-5 antibodies
12/01/2005US20050266007 Activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen; prepared by multiple consecutive dilutions and exposure to external factors; homeopathic technology; urogenital disorders; side effect reduction; cattle extracts; synthetic
12/01/2005US20050266005 Methods and compositions for treating IL-3 related pathologies
12/01/2005US20050266004 Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
12/01/2005US20050266003 Antibodies and their derivatives that induce apoptosis upon binding to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on activatedT cells; autoimmune diseases, transplant rejection, antiallergens, and T cell-derived cancers, anticarinogenic agents;immunosuppressants; induction of immunological tolerance
12/01/2005US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies
12/01/2005US20050266001 Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
12/01/2005US20050266000 Variable domain library and uses
12/01/2005US20050265998 Antibody that binds human Toll-like receptor 4 (TLR4)/human MD-2 complex, wherein antibody inhibits 50% of lipopolysaccharide-induced IL-8 production in solution comprising human TLR4/MD-2 transfected HEK293 cells; therapeutic agents to prevent activation of TLRs in autoimmune, inflammatory disorders
12/01/2005US20050265997 Cancer treatment method by inhibiting MAGE gene expression or function
12/01/2005US20050265996 Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
12/01/2005US20050265995 Tissue targeted complement modulators
12/01/2005US20050265994 Using monclonal antibody for treatment and prevention of discomfort associated with cell proliferative disorders
12/01/2005US20050265993 Methods of treating autoimmune and inflammatory diseases
12/01/2005US20050265987 Sulfatases and methods of use thereof
12/01/2005US20050265966 Methods of treating cancer using IL-21 and monoclonal antibody therapy
12/01/2005US20050265965 Modified cytokines for use in cancer therapy
12/01/2005US20050265924 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
12/01/2005US20050265921 Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
12/01/2005DE102004023187A1 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie Identifying surface-associated antigens for tumor diagnosis and therapy
12/01/2005CA2569094A1 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
12/01/2005CA2568248A1 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
12/01/2005CA2566745A1 Methods of treating cancer using il-21 and monoclonal antibody therapy
12/01/2005CA2566075A1 Microspheres comprising protein and showing injectability at high concentrations of said agent
12/01/2005CA2565804A1 Haplotype markers and methods of using the same to determine response to treatment
12/01/2005CA2565014A1 Isolated nucleic acid molecules encoding a novel phosphoprotein-darpp-32, encoded protein and uses thereof
12/01/2005CA2564538A1 Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
12/01/2005CA2563735A1 Antibodies and molecules derived therefrom that bind to steap-1 proteins
12/01/2005CA2563666A1 Differentially expressed claudin-18 variants in tumors and use thereof
12/01/2005CA2563432A1 Method for augmenting b cell depletion
12/01/2005CA2562800A1 Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
12/01/2005CA2562701A1 Cross-linked antibodies
12/01/2005CA2557053A1 Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/2005
11/30/2005EP1600505A1 Escherichia coli phytase
11/30/2005EP1600460A1 Use of an active substance that binds to CD28 for producing a pharmaceutical composition for treatment of B-CLL
11/30/2005EP1600459A2 Ligand
11/30/2005EP1600165A1 Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent
11/30/2005EP1600164A2 Use of a CD28 binding substance for the production of a pharmaceutical composition with dose-dependent efficacy
11/30/2005EP1599572A2 Compositions and methods for cancer immunotherapy
11/30/2005EP1599504A1 Modified antibody
11/30/2005EP1599503A2 Endothelial cell specific antibodies and uses thereof
11/30/2005EP1599502A1 A molecule which binds cd80 and cd86
11/30/2005EP1599501A2 Modulation of the poliovirus receptor function
11/30/2005EP1599228A2 Modified antibodies to prostate-specific membrane antigen and uses thereof
11/30/2005EP1599227A2 Methods of immunomodulation in animals
11/30/2005EP1599226A1 A method of diagnosis and treatment
11/30/2005EP1599164A2 Methods for treating, preventing and detecting helicobacter infection
11/30/2005EP1418808B1 Imaging marker transgenes
11/30/2005EP1301605B1 Nk cells activating receptors and their therapeutic and diagnostic uses
11/30/2005EP1268766B1 Improvements to ribosome display
11/30/2005EP1196586B1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP1151108B1 The ltr region of msrv-1 and the proteins it encodes, and probes and methods for detecting msrv-1 retrovirus
11/30/2005EP1078063B1 Basb029 polynucleotides and polypeptides from neisseria meningitis
11/30/2005EP1003853B1 Methods for protein screening
11/30/2005CN1703428A Peptides modulating caspase activation
11/30/2005CN1703426A Humanized antibodies that recognize beta amyloid peptide
11/30/2005CN1703240A Lfa-1 alpha subunit antibodies and methods of use
11/30/2005CN1703233A Methods and compositions for preventing oxidative degradation of proteins
11/30/2005CN1701814A F1K-1 is a receptor for vascular endothelial growth factor
11/30/2005CN1229646C Catalytic anti-factor VIII allo-antibodies
11/30/2005CN1229499C Phosphodiesterase 8A
11/30/2005CN1229391C Antibody of human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
11/30/2005CN1229387C Novel human protein with cancer-suppressing function and coding sequence thereof
11/30/2005CN1229386C Novel human protein with function for suppressing cancer and coding sequence thereof
11/30/2005CN1229385C Composition for stimulating megacaryocyte growth and differentiation and process thereof
11/30/2005CN1229139C Prophylactic immune milk preparation against otitis
11/29/2005US6969760 Jak kinases and regulation of cytokine signal transduction
11/29/2005US6969758 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of tumors
11/29/2005US6969601 MASP-2, a complement-fixing enzyme, and uses for it
11/29/2005US6969597 Nucleic acids encoding non aggregating fluorescent proteins and methods for using the same
11/29/2005US6969596 Polynucleotide encoding a human receptor tyrosine kinase
11/29/2005US6969586 isolating from VH- and VL-coding gene repertoires genes coding for an antibody receptor heterodimer capable of binding a preselected ligand
11/29/2005US6969520 Active immunization against clostridium difficile disease
11/29/2005US6969517 Anticancer agents; genetic engineered fusion protein
11/29/2005CA2146964C Particles having gelatin-aminodextran coatings of and processes for making same
11/29/2005CA2118329C Isolation, characterization, and use of the human .beta. subunit of the high affinity receptor for immunoglobulin e
1 ... 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 ... 1494